Matthew W. Foehr

2021 - Ligand Pharmaceuticals

In 2021, Matthew W. Foehr earned a total compensation of $5.3M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 52% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$259,467
Option Awards$1,226,357
Salary$518,933
Stock Awards$3,146,844
Other$130,603
Total$5,282,204

Foehr received $3.1M in stock awards, accounting for 60% of the total pay in 2021.

Foehr also received $259.5K in non-equity incentive plan, $1.2M in option awards, $518.9K in salary and $130.6K in other compensation.

Rankings

In 2021, Matthew W. Foehr's compensation ranked 2,451st out of 12,412 executives tracked by ExecPay. In other words, Foehr earned more than 80.3% of executives.

ClassificationRankingPercentile
All
2,451
out of 12,412
80th
Division
Manufacturing
972
out of 5,498
82nd
Major group
Chemicals And Allied Products
372
out of 2,374
84th
Industry group
Drugs
324
out of 2,095
85th
Industry
Pharmaceutical Preparations
213
out of 1,542
86th
Source: SEC filing on April 22, 2022.

Foehr's colleagues

We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2021.

2021

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2021

Matthew Korenberg

Ligand Pharmaceuticals

Chief Financial Officer

2021

Charles Berkman

Ligand Pharmaceuticals

General Counsel

News

You may also like